HHS 503A Peptide Policy Leaves Research-Use Sellers Out

The U.S. Department of Health and Human Services (HHS) will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six unapproved peptides, BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax, as long as they meet ten conditions set out in an interim enforcement discretion policy that Secretary Robert F. Kennedy Jr. released on October 28, 2026. The policy opens a supervised route through licensed compounding pharmacies. It does nothing for websites that sell the same peptides as “research use only” chemicals, and HHS says pulling buyers away from that market is one of its goals.

The Federal Register notice followed on October 30 (91 FR 68526). It accepts written comments on Docket No. HHS-OASH-2026-0496 for two weeks after publication, which works out to Friday, November 13.

What HHS actually changed

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a licensed pharmacist or physician compound a drug for an individual patient without FDA approval, but only from ingredients that meet one of three tests: a United States Pharmacopeia monograph, a component of an FDA-approved drug, or a place on the 503A bulks list, which the government builds through rulemaking. The HHS policy covers peptides that meet none of those tests.

The new policy does not add them to the bulks list. Instead, HHS says it does not intend to act against compounders who use them while the U.S. Food and Drug Administration (FDA) works through rulemaking, and that the policy applies until each peptide is either added or rejected in a final rule. The notice says FDA’s future rulemakings “may propose adding some or all of these peptides” to the list. The document also states that it “does not establish any rights for any person and is not binding on HHS or the public,” and HHS may revisit it if a safety signal or product quality problem appears.

The status of the policy needs care. The Federal Register notice describes a “draft” policy in one passage and an “interim policy” in the next. The National Association of Boards of Pharmacy (NABP), in an October 28 memo to state pharmacy boards, said that despite the comment period “it appears that this policy is immediately in effect.” The policy itself says public comments may give FDA additional evidence to weigh in that rulemaking.

Six peptides, each limited by form and route

Appendix B of the policy ties each peptide to a specific chemical form and to the routes of administration HHS is willing to tolerate.

Peptide	Form covered	Routes covered
BPC-157	Acetate	Subcutaneous, intramuscular, oral, topical
TB-500	Acetate	Subcutaneous or intramuscular injection
Epitalon	Acetate	Subcutaneous or intramuscular injection, dispensed in intermittent courses
MOTS-c	Acetate	Subcutaneous or intramuscular injection
KPV	Acetate	Topical and oral
Semax	Free base	Intranasal

All six sat in FDA’s Category 2, a group of bulk substances the agency flagged for significant safety risks, from September 2023 until April 22, 2026. The appendix says FDA’s Center for Drug Evaluation and Research recommended against listing each of them, while FDA’s Pharmacy Compounding Advisory Committee voted in favor. HHS justifies overriding the staff view with new certificates of analysis from FDA-registered facilities, newly documented use data and, in some cases, its reading that the earlier safety concerns were “mechanistic rather than observed.” NBC News reported that the advisory committee’s July vote was narrow.

The ten conditions

Enforcement discretion applies only when every condition is met. In summary, the compounded product must:

Use a peptide listed in Appendix A, with the identity and route limits in Appendix B.
Start from bulk material made at an FDA-registered facility and backed by a valid certificate of analysis that meets the testing standard in Appendix B.
Come from an original manufacturer, not just a repacker or distributor, that is registered with FDA, follows current good manufacturing practice and lists its physical location on the certificate. A registered repacker or reseller must document its own validation of that manufacturer.
Be reported. Compounders send FDA’s MedWatch program and the relevant states reports on products compounded, serious adverse events whether or not they appear drug related, and quality problems.
Carry the label “This is a compounded drug product. Not for resale.”
Contain a single active ingredient from Appendix A.
For oral forms, come with documentation that the formulation reaches adequate oral bioavailability in humans.
Use no delivery device other than an FDA 510(k)-cleared syringe.
Meet every other 503A requirement, including sanitary conditions and a valid prescription for an individual patient.

The testing appendix is detailed. It asks for orthogonal identity testing, meaning at least two independent methods, plus assay, impurity, residual solvent, elemental impurity, endotoxin and bioburden results, and it lists the information each certificate should carry, including the manufacturer’s FDA Establishment Identifier (FEI) number, batch and release dates, and a grade statement reading “Intended for human drug compounding.”

Why research-use-only sellers gain nothing

HHS was direct about its motive. The policy says the Secretary determined that it “will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients,” by giving patients “a more controlled alternative.”

Every protection in the policy runs to a compounder working from a prescription. A website that ships vials labeled “for research use only” to consumers is not a state-licensed pharmacy, a federal facility or a physician, so it falls outside the policy entirely. The grade statement HHS expects on a certificate, “Intended for human drug compounding,” is also the opposite of the research-only labeling those sites rely on.

FDA’s position on those sellers has not moved. Its August 2026 warning letters to five online peptide vendors treated research-use disclaimers as no defense when product pages, dosing calculators and bacteriostatic water pointed to human use. States are acting too. The Mississippi Board of Pharmacy said in October that a certificate of analysis alone does not clear a research-grade peptide.

What changes for telehealth peptide programs

For telehealth companies, the policy creates a narrow but usable path. A licensed prescriber can write a patient-specific prescription for one of the six peptides, and a state-licensed 503A pharmacy can compound and dispense it, provided the pharmacy can show the sourcing, testing, labeling and reporting the policy demands.

Several product formats fall outside it. A vial that pairs BPC-157 with TB-500 fails the single-ingredient condition. Oral BPC-157 or KPV needs bioavailability documentation in humans. Semax is covered only as a nasal product, and TB-500, MOTS-c and Epitalon only as injections. A product sold with a pen injector rather than a 510(k)-cleared syringe falls outside the policy. Outsourcing facilities registered under section 503B are not named in the policy, which addresses only 503A compounding.

State law still governs who can prescribe and dispense. A telehealth brand shipping to patients in several states needs prescribers and pharmacies licensed where the patient lives, and a state board can take a stricter view of these peptides than HHS has.

Paperwork that lines up with the policy

For a telehealth site that wants to sell compounded peptides online, the policy’s conditions double as a checklist of records a payment partner may reasonably ask to see. Programs that apply through a high-risk provider such as Organic Payment Gateways can point an underwriter to the dispensing pharmacy’s state licenses, the prescribing workflow, a sample certificate of analysis showing the original manufacturer’s FEI number and the “Intended for human drug compounding” grade, and product labels carrying the required “Not for resale” statement.

Marketing copy is a separate risk. The policy is not an FDA approval, and none of the six peptides is approved for any use. Product pages that promise healing, longevity or weight results still describe unapproved drugs, and nothing in the policy addresses how compounded peptides may be advertised.

Reaction and open questions

HHS spokesperson Emily Hilliard told NBC News the department is “confronting the risks of black-market peptides.” Dr. Peter Lurie, a former FDA official who leads the Center for Science in the Public Interest, told the outlet that FDA was “turning a blind eye” to widen access to drugs that have not been shown to work.

Several points remain open. HHS has not set a timeline for the rulemaking that would decide whether any of the six joins the bulks list, and it has not said how it will respond to comments. The docket showed 190 public comments on the morning of November 11, according to the Federal Register’s regulations.gov summary. The policy can also be narrowed or withdrawn at any time if a safety signal appears.

A narrow opening for licensed pharmacies

HHS’s October 28 policy lets 503A pharmacies and physicians compound BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax under ten conditions covering sourcing, testing, labeling, single-ingredient products, devices and MedWatch reporting, while the peptides stay off the bulks list and remain unapproved. Telehealth programs that build around a licensed pharmacy and a patient-specific prescription gain a defined route. Research-use-only sellers gain none, and HHS has said the policy is meant to draw their customers away. Comments close November 13, and the policy can change after that.

HHS Lets Pharmacies Compound BPC-157 and Five Other Peptides but Leaves Research-Use Sellers Out